(DSS)6-functionalized sEVs delivering miR-126 reduce age-related bone loss in rats
Background
Age-related bone loss, a major public health concern, is characterized by dysregulation of bone homeostasis, leading to increased fracture risk. Current therapeutic strategies often lack specificity or face challenges with efficient delivery of therapeutic agents. Nucleic acid therapeutics, particularly miRNAs, hold promise for treating age-related diseases, but their effective and targeted delivery to bone tissue remains a significant hurdle. Small extracellular vesicles (sEVs) offer a biocompatible delivery platform, and this study explores their engineering to overcome these limitations for age-related bone loss.
Study Design
Researchers engineered small extracellular vesicles (sEVs) to deliver miR-126, creating miR-126 loaded sEVs (m-sEV). These were initially validated in vitro and in a mandibular defect model of aged rats for enhancing vascularized bone regeneration. To optimize systemic delivery, m-sEVs were functionalized with a bone-targeting peptide, (DSS)6, constructing Bm-sEV. Systemic administration of Bm-sEV was then performed in aged rats to assess its impact on bone tissue, focusing on bone microarchitecture, type H vessels, and osteoclastic activity.
Results
Systemic administration of Bm-sEV successfully enabled precise miR-126 delivery to bone tissue in aged rats. This targeted delivery resulted in a significant increase in the abundance of type H vessels in the femur, indicating enhanced vascularization. Furthermore, the treatment led to improved bone microarchitecture and a notable attenuation of age-related bone loss. Mechanistic analyses revealed that the observed angiogenesis-osteogenesis coupling effect was mediated by the upregulation of endothelial Integrin β3 (ITGB3), which subsequently activated the ITGB3/ERK2 signaling cascade. This pathway is crucial for coordinating blood vessel formation and bone regeneration.
Notably, Bm-sEV also restored profoundly impaired osteoclastic activity in aged femurs, thereby re-establishing skeletal homeostasis.
Key Findings
- Engineered sEVs (Bm-sEV) precisely delivered miR-126 to bone tissue in aged rats.
- Bm-sEV treatment increased type H vessel abundance in femurs, enhancing vascularization.
- Improved bone microarchitecture and attenuated age-related bone loss were observed.
- Angiogenesis-osteogenesis coupling was mediated by
ITGB3upregulation andITGB3/ERK2activation. - Bm-sEV restored impaired osteoclastic activity, re-establishing skeletal homeostasis.
Why It Matters
This study presents a promising strategy for treating age-related bone loss by leveraging the synergistic potential of targeted peptide delivery and miRNA therapeutics via sEVs. The use of a (DSS)6 bone-targeting peptide on sEVs could significantly improve the specificity and efficacy of bone-regenerative therapies, reducing off-target effects. This approach moves beyond general systemic administration, suggesting that future protocols for bone health might involve highly localized and precise delivery of biomolecules. While currently preclinical, this work lays groundwork for developing more effective, less invasive treatments that could restore bone homeostasis and reduce fracture risk in the elderly.
age-related-bone-loss
mirna
extracellular-vesicles
bone-targeting
dss-6
osteogenesis